

References

I-85

1. Pharmacy Drug Coverage Policy Manual. North Dakota Department of Health and Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/>
2. Tysabri (natalizumab) injection, for intravenous use [package insert]. Biogen Inc. Cambridge, MA. Revised 04/2023.
3. Corboy JR, Halper J, Langer-Gould AM, et al. Position Statement: Availability of Disease Modifying Therapies (DMT) for the Treatment of Relapsing Forms of Multiple Sclerosis. The American Academy of Neurology (AAN) and the National MS Society (NMSS). 2015.
4. Korzenik J. Natalizumab for treatment of Crohn's disease in adults. In: UpToDate Online Journal [serial online]. Waltham, MA: *UpToDate*; updated January 6, 2015.
5. Olek M. Natalizumab for relapsing-remitting multiple sclerosis in adults. In: UpToDate Online Journal [serial online]. Waltham, MA: *UpToDate*; updated June 4, 2021.
6. White, M., Sariyer, I., Gordon, J., et al. Diagnostic Assays for Polyomavirus JC and Progressive Multifocal Leukoencephalopathy. *Rev Med Virol*. 2016 March; 26(2): 102–114.
7. Brandstadter R, Sand IK. The use of natalizumab for multiple sclerosis. *Neuropsychiatric Disease and Treatment*. 2017;1691-1702.
8. Clerico M, Artusi CA, DiLiberto A, et al. Natalizumab in multiple sclerosis: long-term management. *Int J Mol Sci*. 2017; 18(5):940-952.
9. Clinical Pharmacology Compendia [database online]. 2024.Tampa FL: Gold Standard, Inc. Natalizumab.
- 10.Micromedex®Solutions Compendia. 2024. Natalizumab.
- 11.Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet*. 2018. 17(2):162-173.
- 12.Bross M, Hackett M, Bernitsas E. Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis. *Int J Mol Sci*. 2020;21(12):4312.
- 13.Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. *JAMA Neurology*. 2020;77(2):184-191.
- 14.Butzkueven H, Trojano M, Kappos L, et al. Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP). *Mult Scler*. 2021;27(3):410-419.

15. Nelson SM, Nguyen TM, McDonald JW, MacDonald JK. Natalizumab for induction of remission in Crohn's disease. *Cochrane Database Syst. Rev.* 2018, 8, Cd006097.
16. Natalizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 19, 2022.
17. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. *Gastroenterology*. 2018;155(3):696-704
18. Tyruko® (natalizumab-sztn) injection, for intravenous use [package insert]. Sandoz Inc., Princeton, NJ. Revised 08/2023.